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Abstract
Background: Visceral Fat Area (VFA) is an independent predictor of coronary disease. While low density lipoprotein
cholesterol (LDL-C) is used to determine risk and guide therapy, its accuracy fails in obese patients who may have
low LDL-C despite high VFA.
Objective: We sought to describe the relationship between VFA, LDL-C and to describe shifting cholesterol
metabolism with increasing VFA.
Methods: 42 High-risk vascular patients not on lipid-lowering therapy provided a fasting lipid profile and
underwent magnetic resonance imaging (MRI) to quantify VFA and subcutaneous fat area (SFA) at the L4-L5 disc.
Comparisons: 1. Correlation between VFA, SFA, LDL-C and the standard lipid panel 2. Correlation between VFA, SFA
and markers of cholesterol synthesis (desmosterol, lathosterol) and cholesterol absorption (cholestanol, sitosterol).
Results: VFA was inversely correlated with LDL-C (r = -0.348) indicating potential discordance between
cardiovascular risk and LDL-C. However, VFA was appropriately correlated with other markers of increased risk: r =
-0.361 with HDL-C, r = 0.503 with VLDL-C, r = 0.499 with TG (all p < 0.05). VFA did not correlate significantly with
non-HDL-C. VFA correlated positively with cholesterol synthesis markers (desmosterol, lathosterol) and negatively
with an absorption marker (cholestanol).
Conclusions: LDL-C is inversely correlated with VFA and this may explain the loss of the relationship between
LDL-C and cardiovascular events in the obese. While Non-HDL-C did not correlate positively with VFA, the absence
of a negative correlation suggests that it may be a more appropriate lipid target in an increasingly obese world.
Introduction
Visceral fat area (VFA), measured at the umbilicus, has
been independently linked to the development of coron-
ary artery disease (CAD) while subcutaneous fat area
(SFA) has not been shown to carry prognostic signifi-
cance [1]. The accumulation of visceral adipose tissue is
associated with the adverse metabolic consequences of
obesity and VFA is a better predictor of cardiovascular
risk factors than body mass index (BMI), even in non-
obese individuals [1-6]. However, in determining patient
risk and tailoring therapy, clinicians rarely quantify fat
areas using imaging modalities and typically rely on the
standard lipid panel. The current target of therapy is
low density lipoprotein cholesterol (LDL-C) which
shows a log-linear relationship with cardiovascular
events in both primary and secondary prevention [7].
However, several reports have highlighted the loss of the
relationship between LDL-C and subsequent cardiovas-
cular events, as reviewed previously [6]. In a cohort
from the Lipid Research Clinics prevalence study, men
with LDL-C <100 mg/dl, had an increased cardiovascu-
lar mortality when compared to men with LDL-C in the
100-130 mg/dl range and hence the log-linear relation-
ship between LDL-C and coronary events appears inva-
lid, especially in patients with high triglycerides (TG)
>200 mg/dl [8]. Similarly, an analysis of diabetic patients
(average TG 254 mg/dl) also suggests a dissociation
between CAD death and LDL-C [9]. In a large cohort of
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any medium, provided the original work is properly cited.patients with CAD, diabetes was identified as a predictor
of lower LDL-C levels; despite diabetics being at higher
risk for cardiovascular events [10]. Indeed, the epide-
miological studies on the basis of which the Adult
Treatment Panel III (ATPIII) formulated guidelines
were from an era when diabetes, obesity and the meta-
bolic syndrome were less prevalent [6].
LDL-C has been criticized as a target of therapy that
does not take into account very low-density lipoprotein
cholesterol (VLDL-C) which predicted coronary events
independently of LDL-C in the Framingham cohort [11].
The current ATPIII guidelines only recommend the
consideration of the VLDL-C fraction in patients with
hypertriglyceridemia. Non-High density lipoprotein cho-
lesterol (non-HDL-C), calculated as total cholesterol
minus high density lipoprotein cholesterol (TC - HDL-
C) is recommended as a secondary target of therapy in
patients with TG >200 mg/dl and takes into account the
VLDL-C fraction [12]. However, non-HDL-C is superior
to LDL-C in predicting CAD events regardless of
whether TG is greater than or less than 200 mg/dl
[6,11]. In order to more accurately assess the relation-
ship between obesity and the lipid panel, we sought to
describe the relationship between VFA, SFA, LDL-C,
VLDL-C and non-HDL-C. Since increasing levels of
VLDL-C are associated with increasing hepatic choles-
terol synthesis [13,14], we also related VFA and SFA to
cholesterol synthesis markers (desmosterol, lathosterol)
and cholesterol absorption markers (cholestanol and
sitosterol) to determine the relationship between choles-
terol metabolism and visceral adiposity.
Methods
Study Population
We recruited patients with established vascular disease
into this study. All patients had documented coronary
artery disease (CAD), ischemic stroke or CAD risk-
equivalents and thus represent e dah i g h - r i s kc o h o r te l i -
gible for aggressive lipid-lowering therapy. Eligible
patients had to have at least one of the following: 1.
CAD (positive angiogram or history of myocardial
infarction) 2. peripheral vascular disease (ABI <0.9 or
history of lower limb revascularization for atherosclero-
sis) 3. abdominal aortic aneurysm 4. carotid athero-
sclerosis with >50% narrowing 5. type II diabetes with
age >50 and 3 additional risk factors (male sex, albumi-
nuria, hypertension, HDL-C <40 mg/dl, TG >150 mg/dl,
LDL-C >100 mg/dl, current smoking, diabetes duration
>20 years) or 6. ischemic stroke. Study participants were
in a clinically stable condition and were recruited from
the vascular surgery outpatient department at the Royal
Brisbane & Women’sH o s p i t a l( R B W H ) .T oe n s u r e
accurate assessment of endogenous cholesterol metabo-
lism, patients treated with any statin, ezetimibe or
stanol/sterol spreads at baseline were excluded. This
study is approved by the RBWH research ethics com-
mittee (2005/006A) and all study participants gave
informed consent.
Patient Data
Patient demographic information was collected includ-
ing age, sex, qualifying criterion, self-reported race,
height, weight, waist and hip circumferences. Fasting
blood samples were analyzed for baseline lipids, glucose,
insulin, high sensitivity C-reactive protein (CRP), choles-
tanol, sitosterol, desmosterol and lathosterol. To deter-
mine insulin sensitivity, we used the Quantitative insulin
sensitivity check index (QUICK Index) since this a
superior linear correlate (r~0.8-0.9) of the reference
standard glucose clamp than the Homeostasis model
assessment (HOMA) model [15,16].
MRI Measurement of Abdominal Fat Areas
MR imaging was performed with a Siemens Trio 3 T
MRI system (Erlangen, Germany) using standard array
coils with the subject supine. Breath-hold FISP images
were centered on the L4-L5 intervertebral disc using
standard localizer images with the following parameters:
TR = 4 ms, TE = 2 ms, number of slices = 12, slice
thickness = 8 mm, image matrix 256 × 256, field-of-
view = 500 × 500 mm. The 4 slices that were best
aligned with the L4-L5 disc (19, 20), were analyzed by a
single operator (MRH) using the polygon region of
interest in Escape Medical Viewer v3.2 to define visceral
fat area (VFA) and subcutaneous fat area (SFA) as
described previously [17]. Briefly, VFA and SFA were
measured by fitting a spline curve to points on the bor-
der of the subcutaneous and visceral regions. Nonfat
regions within the visceral region were also outlined
with a spline fit and subtracted from the total visceral
region.
Laboratory Methodology
Fasting lipid profile was determined using standard hos-
pital methods and LDL-C was indirectly measured using
the Friedewald method. CRP was determined by high-
sensitivity immunonephelometry. Insulins were mea-
sured by Chemilumnescent Immunoassay on a Beckman
Coulter DxI800 as per the manufacturer’s instructions.
Cholestanol, sitosterol, desmosterol and lathosterol were
measured using gas chromatography/ mass spectrometry
(GCMS) (Agilent, Model 6890/ 5973 using Chemstation
software). Internal standards were 5-a-cholestane for
cholestanol, D7 sitosterol for sitosterol and D4 lathos-
terol for both lathosterol and desmosterol. Plasma (50
μL) was assayed with the addition of internal standards.
The sample was then saponified at 60 degrees Celsius
for 60 minutes using potassium hydroxide and extracted
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combining organic layers. Combined organic layers were
dried under nitrogen and the residue derivatised with
bistrimethylsilyl trifluoroacetic anhydride/ 1% trimethyl-
chlorosilane (BSTFA/TMCS) to form trimethylsilyl deri-
vatives. The final derivatised extract (1 μL) was injected
into the GCMS system and sterols separated using a
capillary column DB 5 MS type (length 30 m, 0.25 mm
internal diameter and 0.25 micron film thickness). Diag-
nostic ions specific for cholestanol, sitosterol, desmos-
terol, lathosterol and internal standards were monitored
and the ratio of the sterol target ions to their respective
internal standard ions was calculated and related to a
calibration curve. The calibration curve was based on
spiked normal plasma corrected for endogenous sterol
levels using the technique of standard addition. Inter
and intra-run coefficients of variation were 5% and 3%
respectively. Linearity (r
2 = 0.998) was established
beyond physiological values.
Statistical Methods
The QUICK Index of insulin sensitivity for each subject
was calculated as 1/[log (fasting insulin, μU/ml) + log
(fasting glucose, mg/dl)] [15]. We first undertook uni-
variate correlation with VFA or SFA as the dependent
variable and the baseline fasting lipid panel, fasting glu-
cose, fasting insulin and QUICK Index as independents.
Skewed distributions were log-transformed. This was
followed by correlations between VFA, SFA and various
markers of cholesterol metabolism. All analyses were
done with statistics software (SPSS 16).
Results
Forty three patients were enrolled in this study. One
patient was removed from this analysis because of
hypertriglyceridemia (TG > 400 mg/dl), rendering indir-
ect methods of LDL-C determination inaccurate leaving
42 patients in this analysis. Baseline characteristics,
including baseline lipid panel, CRP, cholesterol synthesis
markers (lathosterol, desmosterol) and cholesterol
absorption markers (cholestanol, sitosterol) were avail-
able in all patients. The baseline characteristics of the
42 patients who are included in this analysis are shown
in Table 1. Summary statistics for the baseline lipid
panel and cholesterol metabolism markers are shown in
Table 2. In order to explore the relationship between
visceral fat area (VFA), subcutaneous fat area (SFA) and
metabolic parameters, we undertook univariate correla-
tion between VFA, SFA and components of the lipid
panel, CRP, fasting glucose, insulin and the QUICK
Index of insulin sensitivity. The results of univariate cor-
relation are shown in Table 3. Concordant with previous
reports, VFA is a more consistent correlate of metabolic
parameters than SFA. SFA was not significantly
correlated to VLDL-C, triglycerides or fasting glucose.
Hence, in our cohort, VFA overall appears a superior
correlate to the adverse metabolic consequences of obe-
sity. A noteworthy finding was the significant negative
correlation between LDL-C and VFA (r = -0.348, p =
0.024). Hence, while higher VFA has been independently
associated with an increased risk of CAD, VFA is inver-
sely correlated to LDL-C and thus patients with higher
a m o u n t so fV F Am a yh a v el o w e rL D L - C .H e n c e ,t h i s
might explain the ‘disconnect’ between LDL-C and sub-
sequent clinical events observed in patients with dia-
betes and hypertriglyceridemia [6,8,11].
Moreover, VFA was a strong positive correlate of VLDL-
C which is predictive of coronary events independently of
LDL-C [6,11]. VLVL-C is not routinely considered for risk
assessment in the current ATPIII guidelines. Since
increasing VLDL-C is indicative of increased hepatic
synthesis of cholesterol, we tested this more formally by
assessing the relationships between VFA, SFA and choles-
terol synthesis markers (desmosterol, lathosterol) and
Table 1 Patient Characteristics of Patients Included in the
Analysis
Mean ± SD or n (%)
Age 70 ± 8
Males 34 (81)
Females 8 (19)
Race
White 41 (98)
Non-White 1 (2)
Height (cm) 172 ± 10
Weight (kg) 78 ± 19
Body Mass Index 26 ± 5
Waist (cm) 101 ± 16
Hip (cm) 101 ± 13
Diabetic 10 (24)
Metabolic Syndrome by ATP III Criteria 22 (52)
Fasting Glucose (mg/dl) 115 ± 37
Fasting Insulin (mU/L) 7 ± 4
QUICK .25 ± .02
Visceral Fat Area (cm
2) 202 ± 112
Subcutaneous Fat Area (cm
2) 239 ± 115
Percent Visceral Fat Area 45 ± 12
Qualifying Criterion*
Coronary Artery Disease 10 (24)
Peripheral Vascular Disease 23 (55)
Carotid Atherosclerosis >50% 12 (29)
Abdominal Aortic Aneurysm 10 (24)
Ischemic Stroke 8 (19)
Diabetes 10 (24)
*Patients frequently had >1 inclusion criterion.
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terol). The results of this analysis are shown in Table 4.
While neither VFA nor SFA correlated with sitosterol (an
absorption marker), VFA correlated negatively with cho-
lestanol (an absorption marker) and positively with synth-
esis makers desmosterol and lathosterol or their ratios.
Hence, VFA is consistently associated with another
metabolic trait of obesity, increased cholesterol synthesis
and decreased cholesterol absorption [18], while SFA is
not. This shift in phenotype is reflected by the positive
correlation between VFA and VLDL-C and this shift in
cholesterol metabolism is not reflected when LDL-C is
considered in isolation to guide lipid-lowering therapy.
Discussion
Our most important finding is the negative correlation
between VFA, which independently predicts the devel-
opment of CAD [1], and LDL-C which is the primary
therapeutic target recommended by the ATPIII guide-
lines for the prevention and treatment of coronary dis-
ease. This observation might explain the ‘disconnect’
between LDL-C and subsequent clinical events which
h a sb e e no b s e r v e di np a t i e n t sw i t hd i a b e t e sa n dh y p e r -
triglyceridemia [6,8,11]. However, VFA was a strong
positive correlate of VLDL-C which is predictive of cor-
onary events independently of LDL-C [11]. Non-HDL-C,
which for practical purposes is the sum of LDL-C and
VLDL-C, did not correlate with VFA or SFA and thus
may be more useful in patients with higher degrees of
visceral adiposity since it is not spuriously decreased as
LDL-C is. VFA correlated negatively with cholestanol, a
cholesterol absorption marker and positively with synth-
esis makers, desmosterol and lathosterol or their ratios.
This shift in phenotype with obesity concordant with
the positive association between VFA and VLDL-C; an
effect that is not captured by isolated consideration of
LDL-C. To provide an illustrative example of this, we
compared the LDL-C in patients with and without the
metabolic syndrome in our cohort. The metabolic syn-
drome is associated with an increased risk of cardiovas-
cular events in vascular populations similar to ours and
Table 2 Summary Population Lipids and CRP at Baseline
Baseline value
(mean ± SD)
Total Cholesterol (mg/dl) 212 ± 34
LDL cholesterol (mg/dl) 138 ± 33
HDL cholesterol (mg/dl) 45 ± 16
Non-HDL cholesterol (mg/dl) 167 ± 33
VLDL cholesterol 29 ± 14
Triglycerides (mg/dl) 146 ± 72
CRP (mg/L) 3.53 ± 2.47
Cholestanol (μmol/L) 7.03 ± 2.73
Desmosterol (μmol/L) 2.77 ± 0.94
Lathosterol (μmol/L) 5.88 ± 3.18
Sitosterol (μmol/L) 6.31 ± 3.65
Cholestanol:cholesterol ratio (μmol cholestanol/
mmol cholesterol × 100)*
126 ± 40
Desmosterol:cholesterol ratio (μmol desmosterol/
mmol cholesterol × 100)
51 ± 16
Lathosterol:cholesterol ratio (μmol lathosterol/
mmol cholesterol × 100)
109 ± 62
Sitosterol:cholesterol ratio (μmol sitosterol/mmol
cholesterol × 100)
112 ± 57
*this format is adopted for ease of comparison with previous reports;
synthesis and absorption markers are standardized to total cholesterol.
Table 3 Univariate Correlations of Visceral Fat Area,
Subcutaneous Fat Area with Components of the Lipid
Panel, Glucose, Insulin and the QUICK Index
Visceral Fat Area;
Pearson’s r, (p-value)
Subcutaneous Fat Area;
Pearson’s r, (p-value)
Total
Cholesterol
-.306 (.049) -.142 (.370)
LDL
Cholesterol
-.348 (.024) -.068 (.668)
HDL
Cholesterol
-.361 (.019) -.339 (.028)
Non-HDL
Cholesterol
-.139 (.381) .029 (.857)
VLDL
Cholesterol
.503 (.001) .217 (.168)
Triglycerides .499 (.001) .226 (.151)
CRP .111 (.484) .000 (.995)
Fasting
Glucose
.522 (<.001) .111 (.486)
Insulin .664 (<.001) .682 (<.001)
QUICK Index -.723 (<.001) -.592 (<.001)
Table 4 Univariate Correlations of Visceral Fat Area,
Subcutaneous Fat Area and Markers of Cholesterol
Synthesis (Desmosterol, Lathosterol) and Cholesterol
Absorption (Cholestanol, Sitosterol)
Visceral Fat Area;
Pearson’s r, (p-value)
Subcutaneous Fat Area;
Pearson’s r, (p-value)
Cholestanol -.433 (.004) -.270 (.084)
Cholestanol:
cholesterol ratio;
CCR
-.357 (.020) -.236 (.132)
Desmosterol .264 (.092) .158 (.317)
Desmosterol:
cholesterol ratio;
DCR
.421 (.006) .232 (.140)
Lathosterol .404 (.008) .528 (<.001)
Lathosterol:
cholesterol ratio;
LCR
.454 (.003) .548 (<.001)
Sitosterol -.248 (.114) -.273 (.080)
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with the metabolic syndrome in our cohort had greater
visceral fat areas (263 vs 134 cm
2, P < 0.01) but lower
LDL-C (126 vs 153 mg/dl, p < 0.01) compared to
patients without the metabolic syndrome. Hence
patients in our cohort with the metabolic syndrome
who are at an increased risk for future cardiovascular
events may be incorrectly deemed lower risk by isolated
consideration of LDL-C on the standard lipid panel.
Several larger studies have correlated VFA to total
cholesterol and have shown both significant positive and
negative correlation of total cholesterol and VFA [4,23].
However, total cholesterol is no longer the primary tar-
get of lipid-lowering therapy. Studies that have related
LDL-C to obesity measures such as BMI have also
shown both positive and negative associations. While
excess body weight has been consistently associated
with increases in TG, VLDL-C and decreased HDL-C,
the effects of body weight on LDL-C have been variable
[24-28]. In our study, the ‘gold standard’ measure of
adiposity, the visceral fat area, in fact showed a negative
correlation with LDL-C. The implications of this finding
are that high-risk patients with large amounts of visceral
a d i p o s et i s s u em a yn o tq u a l i f yf o rd r u gt h e r a p yb a s e d
on the current ATPIII guidelines, despite being at
increased risk for coronary disease [1]. LDL-C has been
criticized as an increasingly obsolete therapeutic target
in the face of a growing obesity epidemic and non-
HDL-C has been proposed as a more appropriate thera-
peutic target which incorporates the VLDL-C fraction
and therefore better capitulates shifting cholesterol
metabolism with obesity [6]. In our cohort, non-HDL-C
did not correlate significantly with VFA and therefore
may be a more appropriate target of therapy than LDL-
C that can be applied ‘across the board’ in both lean
and obese individuals. However, since non-HDL-C did
not correlate positively with VFA, it is perhaps not the
ideal therapeutic target since it did not capture the
increased risk associated with increased visceral adipose
tissue.
ApoB, which reflects the total number of atherogenic
lipid particles, is widely regarded as the ‘gold standard’
for assessing cardiovascular risk and guiding therapy
[29,30]. ApoB correlates positively with visceral fat area
and may therefore best capture the increased cardiovas-
cular risk with increasing visceral adiposity [23]. ApoB
concentrations added to the predictive value of LDL-C
i nt h eQ u e b e cH e a r tS t u d yw h i c hw a sap r o s p e c t i v e
cohort followed for 13 years [31]. While non-HDL-C
was a superior correlate of apoB than LDL-C, there
remains some discordance between non-HDL-C and
ApoB [32,33]. While non-HDL-C is superior to LDL-C
in cardiovascular risk prediction, it may not fully reflect
risk associated with the smaller LDL particles which is a
hallmark of obesity and insulin resistance [34]. Unfortu-
nately, ApoB assays are not routine in Australia or in
many parts of the world and we were unable to assess
ApoB in our cohort. On a World-wide basis, the stan-
dard lipid panel remains the mainstay of lipid assess-
ment. In this context, non-HDL-C as a therapeutic
target may be superior to LDL-C and has the advantage
of not being spuriously low in patients with greater
amounts of visceral adipose tissue and an increased risk
for cardiovascular events.
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